A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT04875195

Title field or adapter rule

{'original_value': "A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)", 'source_field': 'protocolSection.identificationModule.officialTitle'}

Ingested At

2026-11-01T01:03:15.955217+00:00

Published At

2025-02-10T00:00:00+00:00

Record Updated At

2026-10-27

Results Posted At

2025-02-10

Source Retrieved At

2026-11-01T01:03:15.424322+00:00

Timestamp Basis

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Date limitation

ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Hodgkin\u0027s Lymphoma", "Primary Mediastinal Large B-cell Lymphoma (PMBCL)"]

protocolSection.statusModule.lastUpdatePostDateStruct

{"date": "2026-10-27", "type": "ACTUAL"}

protocolSection.identificationModule.nctId

"NCT04875195"

protocolSection.identificationModule.officialTitle

"A Phase 2 Study of Pembrolizumab (MK-3475) Every 6 Weeks (Q6W) in Participants With Relapsed or Refractory Classical Hodgkin\u0027s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL)"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct

{"date": "2025-02-10", "type": "ACTUAL"}

Study condition terms

• Hodgkin's Lymphoma (protocolSection.conditionsModule.conditions)
• Primary Mediastinal Large B-cell Lymphoma (PMBCL) (protocolSection.conditionsModule.conditions)

Interventions recorded in this study

• {'armGroupLabels': ['Arm 1'], 'description': 'Pembrolizumab, 400 mg, Q6W, intravenous (IV) infusion.', 'name': 'Pembrolizumab', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.